Q2 2026 13F · SEC CIK 1381843

Atle Fund Management AB

Asset managerFiled 2026-07-24 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $371.7M
Reported positions: 39
Top holdings a year, 3 yrs: +9.7%
Average holding period: 2.2 yrs

Atle Fund Management AB is an asset manager that reported 39 positions worth $371.7M in its Q2 2026 13F, filed 2026-07-24. Its largest holdings were Lilly Eli & Co (LLY, 9.6%), Merck & Co. Inc (MRK, 6.5%), Johnson & Johnson (JNJ, 5.8%). A portfolio copying its top holdings returned 9.7% a year over the last 3 years, against 18.8% for the S&P 500.

Atle Fund Management AB holdings all 39 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Atle Fund Management AB 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
LLYLilly Eli & Co	9.6%	8.7%	29,821	-24.9%	$35.8M
MRKMerck & Co. Inc	6.5%	7.4%	189,357	+459.4%	$24.3M
JNJJohnson & Johnson	5.8%	3.9%	85,425	-7.5%	$21.7M
ABBVAbbvie Inc	4.4%	3.4%	64,325	-40.5%	$16.2M
CVSCvs Caremark Corporation	4.1%	3.0%	146,102	+514.6%	$15.1M
TMOThermo Fisher Scientific Inc	3.8%	4.7%	27,859	+21.2%	$14.0M
RVMDRevolution Medicines Inc	3.7%	2.9%	73,077	-88.2%	$13.7M
BIIBBiogen Inc	3.6%	New	62,781	—	$13.6M
NBIXNeurocrine Biosciences Inc	3.3%	2.5%	72,898	-18.7%	$12.3M
MIRMMirum Pharmaceuticals Inc	3.2%	3.0%	100,807	-48.5%	$11.8M
ALKSAlkermes PLC	3.0%	2.7%	213,329	-12.0%	$11.2M
IONSIonis Pharmaceuticals Inc	2.9%	3.0%	137,131	+392.0%	$10.9M
ONCBeone Medicines Ltd	2.7%	3.9%	35,180	-15.7%	$10.0M
ISRGIntuitive Surgical Inc	2.6%	3.0%	24,656	-65.2%	$9.8M
SYKStryker Corporation	2.6%	3.1%	30,283	+12.8%	$9.5M
VRTXVertex Pharmaceuticals Inc	2.6%	3.6%	19,131	-16.8%	$9.5M
EWEdwards Lifesciences Corp	2.5%	2.7%	103,230	-3.1%	$9.3M
BBIOBridgebio Pharma Inc	2.5%	3.8%	124,707	+12.0%	$9.3M
KRYSKrystal Biotech Inc	2.4%	2.2%	24,019	-36.1%	$8.9M
CORCencora Inc Com	2.4%	2.1%	31,126	+32.6%	$8.8M
NAMSNewamsterdam Pharma Company	2.3%	1.8%	248,848	+162.5%	$8.4M
ABVXAbivax SA	2.1%	1.5%	58,170	+84.1%	$7.8M
INCYIncyte Corp	1.7%	2.6%	56,953	+12.1%	$6.5M
IRTCIrhythm Holdings Inc	1.7%	2.0%	54,102	+142.4%	$6.4M
BSXBoston Scientific Corp	1.7%	2.9%	146,381	+262.0%	$6.2M
INSMInsmed Inc	1.7%	1.9%	58,378	-40.1%	$6.2M
TNGXTango Therapeutics Inc	1.7%	1.2%	198,557	+563.7%	$6.2M
GILDGilead Sciences	1.6%	2.3%	46,142	-3.8%	$5.8M
CAHCardinal Health Inc	1.5%	1.5%	23,630	-78.3%	$5.6M
ORKAOruka Therapeutics Inc	1.4%	New	54,886	—	$5.2M
SYRESpyre Therapeutics	1.4%	1.1%	57,030	-9.1%	$5.1M
DXCMDexcom Inc	1.3%	0.9%	71,846	-87.7%	$4.8M
BCAXBicara Therapeutics Inc	1.2%	0.7%	145,657	-87.5%	$4.3M
IDYAIdeaya Biosciences Inc	0.9%	1.3%	94,478	+203.5%	$3.5M
CELCCelcuity Inc	0.9%	1.7%	33,313	-76.4%	$3.5M
IRONDisc Medicine Inc	0.9%	1.0%	43,682	-59.3%	$3.2M
PYXSPyxis Oncology Inc	0.8%	0.5%	966,459	+390.5%	$2.9M
CMPXCompass Therapeutics Inc	0.6%	1.0%	1,048,593	+2406.7%	$2.3M
008064206Jade Biosciences Inc	0.5%	New	88,556	—	$2.0M

What Atle Fund Management AB bought and sold in Q2 2026, against Q1 2026.

New positions

BIIB Biogen Inc3.6% of 13F
ORKA Oruka Therapeutics Inc1.4% of 13F
Jade Biosciences Inc0.5% of 13F

Added to

CMPX Compass Therapeutics Inc+2406.7% shares
TNGX Tango Therapeutics Inc+563.7% shares
CVS Cvs Caremark Corporation+514.6% shares
MRK Merck & Co. Inc+459.4% shares
IONS Ionis Pharmaceuticals Inc+392.0% shares
PYXS Pyxis Oncology Inc+390.5% shares
BSX Boston Scientific Corp+262.0% shares
IDYA Ideaya Biosciences Inc+203.5% shares

Reduced

RVMD Revolution Medicines Inc-88.2% shares
DXCM Dexcom Inc-87.7% shares
BCAX Bicara Therapeutics Inc-87.5% shares
CAH Cardinal Health Inc-78.3% shares
CELC Celcuity Inc-76.4% shares
ISRG Intuitive Surgical Inc-65.2% shares
IRON Disc Medicine Inc-59.3% shares
MIRM Mirum Pharmaceuticals Inc-48.5% shares

Sold out

Share counts compared with the Q1 2026 13F; a split also changes share counts.

How the holdings did against the S&P 500.

1 year: +31.1% /yr; S&P 500 +20.1%
3 years: +9.7% /yr; S&P 500 +18.8%
5 years: +10.9% /yr; S&P 500 +9.8%

A portfolio of the filer's 20 largest 13F positions, weighted by value and rebuilt each quarter on the day the filing became public. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$371.7M	39
Q1 2026	$309.7M	39
Q4 2025	$313.4M	39
Q3 2025	$27.0M	38
Q2 2025	$233.7M	37
Q1 2025	$226.5M	37
Q4 2024	$210.8M	36
Q3 2024	$212.8M	36
Q2 2024	$164.0M	38
Q1 2024	$164.4M	44
Q4 2023	$127.8M	45
Q4 2022	$51.8M	53

Questions about Atle Fund Management AB's portfolio

What stocks does Atle Fund Management AB own?

Atle Fund Management AB's latest 13F, for Q2 2026 and filed Jul 24, 2026, lists 39 positions worth $371.7M. The largest are Lilly Eli & Co (LLY) at 9.6%, Merck & Co. Inc (MRK) at 6.5%, Johnson & Johnson (JNJ) at 5.8%, Abbvie Inc (ABBV) at 4.4% and Cvs Caremark Corporation (CVS) at 4.1%.

What did Atle Fund Management AB buy last quarter?

In Q2 2026, Atle Fund Management AB added a new position in Biogen Inc (BIIB), a new position in Oruka Therapeutics Inc (ORKA), a new position in Jade Biosciences Inc, Compass Therapeutics Inc (CMPX) (+2406.7% shares), Tango Therapeutics Inc (TNGX) (+563.7% shares) and Cvs Caremark Corporation (CVS) (+514.6% shares), compared with its Q1 2026 filing.

What did Atle Fund Management AB sell last quarter?

In Q2 2026, Atle Fund Management AB sold all of Amgen Inc Com (AMGN), sold all of Unitedhealth Group Inc Com (UNH), sold all of Soleno Therapeutics Inc (SLNO), Revolution Medicines Inc (RVMD) (-88.2% shares), Dexcom Inc (DXCM) (-87.7% shares) and Bicara Therapeutics Inc (BCAX) (-87.5% shares), compared with its Q1 2026 filing.

How has Atle Fund Management AB's portfolio performed?

A portfolio copying Atle Fund Management AB's 20 largest 13F holdings each quarter, from the day each filing was public, returned +9.7% a year over the last 3 years, against +18.8% for the S&P 500. Over 1 year: +31.1% against +20.1%. Over 5 years: +10.9% a year against +9.8%.

When is Atle Fund Management AB's next 13F filing due?

13F filings are due 45 days after each quarter ends. Atle Fund Management AB's filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.